rifaquizinone

Rifaquizinone is a **novel, dual-pharmacophore, small molecule antibiotic** that combines the pharmacophores of rifamycin and a fluoroquinolone-like compound in a single molecule. It is designed for **treatment of serious or life-threatening bacterial infections**, especially those associated with drug-resistant gram-positive pathogens and biofilm-associated device infections. Mechanistically, it exerts potent bactericidal activity through **inhibiting bacterial RNA polymerase, DNA gyrase, and DNA topoisomerase IV**. Key indications under investigation include **acute bacterial skin and skin structure infections (ABSSSI)**, **prosthetic joint infections (PJI)**, **biofilm-associated infections**, **hepatic encephalopathy**, and **irritable bowel syndrome with diarrhea (IBS-D)**. Additional investigational indications have included **gastrointestinal tract infections**, **superbug and diabetic foot infections**, **hyperammonemia**, and **helicobacter pylori infection**.

Brand names

rifaquizinone

Other names

rifaquizinoneTNP-2092TNP2092TNP 2092CBR-2092CBR2092CBR 2092RFQ